Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Critical vasospasm during fingolimod (FTY720) treatment in a patient with multiple sclerosis.

× No keyword cloud information.

10 in total

Review 1. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors: Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal: Nat Rev Drug Discov Date: 2010-10-29 Impact factor: 84.694

Review 2. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Authors: Lesley J Scott
Journal: CNS Drugs Date: 2011-08 Impact factor: 5.749

3. FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.

Authors: Léon J A Spijkers; Astrid E Alewijnse; Stephan L M Peters
Journal: Br J Pharmacol Date: 2012-06 Impact factor: 8.739

Review 4. Treatment of multiple sclerosis: current concepts and future perspectives.

Authors: Dorothea Buck; Bernhard Hemmer
Journal: J Neurol Date: 2011-06-03 Impact factor: 6.682

5. Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility.

Authors: Lillian Cruz-Orengo; Brian P Daniels; Denise Dorsey; Sarah Alison Basak; José G Grajales-Reyes; Erin E McCandless; Laura Piccio; Robert E Schmidt; Anne H Cross; Seth D Crosby; Robyn S Klein
Journal: J Clin Invest Date: 2014-05-08 Impact factor: 14.808

Review 6. Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 1.

Authors: Aryan Rafiee Zadeh; Mozhde Askari; Niloufar Nasr Azadani; Akram Ataei; Keyvan Ghadimi; Nooshin Tavoosi; Masih Falahatian
Journal: Int J Physiol Pathophysiol Pharmacol Date: 2019-08-15

Review 7. Fingolimod: therapeutic mechanisms and ocular adverse effects.

Authors: P Mandal; A Gupta; W Fusi-Rubiano; P A Keane; Y Yang
Journal: Eye (Lond) Date: 2016-11-25 Impact factor: 3.775

8. Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease.

Authors: Katja Thomas; Hagen Schrötter; Michael Halank; Tjalf Ziemssen
Journal: BMC Neurol Date: 2014-06-07 Impact factor: 2.474

9. A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.

Authors: Hans Lindå; Anders von Heijne
Journal: Front Neurol Date: 2015-03-04 Impact factor: 4.003

10. Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.

Authors: James J Marriott
Journal: J Cent Nerv Syst Dis Date: 2011-03-16

10 in total